Post Market Clinical Follow-Up of the Zimmer Stafit Acetabular System

Terminated

Conditions: Osteoarthritis, Hip
Fracture of Hip
Post-traumatic; Arthrosis
Subluxation Hip
Avascular Necrosis of Hip
Rheumatoid Arthritis
Osteonecrosis
Dislocated Hip

Brief Summary: This study is a Post Market Clinical Follow up study to fulfil the post market surveillance obligations according to Medical Device Directive and European Medical Device Vigilance System (MEDDEV) 2.12-2. The data collected from this study will serve the purpose of confirming safety and performance of the Zimmer Stafit Acetabular System.

Detailed Description: The objective of this study is to obtain implant survival and outcome data on the Stafit Acetabular System by analysis of standard scoring systems, radiographs, and adverse event records.

Data will be used to monitor pain, mobility, dislocation rate and implant survival, and to confirm the long-term safety and performance of the Stafit Acetabular System in primary total hip arthroplasty.

The study design is a multi-center, prospective, non-controlled, consecutive cohort post market clinical follow-up study, involving orthopedic surgeons skilled in total hip arthroplasty procedures and experienced with the Stafit Acetabular System.

Recruitment & Eligibility

Inclusion Criteria

Males and females
Patients suffering from severe hip pain and disability requiring a primary total hip arthroplasty.
18 years minimum
Patients able to participate in a follow-up program based upon physical examination and medical history
Patients who have provided written informed consent by signing the Patient Informed Consent Form.

Exclusion Criteria

Patients who are unwilling or unable to give informed consent, or to comply with the follow-up program
Known pregnancy
Revision hip arthroplasty

Primary Outcome Measures

Name	Time	Method
Dislocation Rate	2 years	Assessed by counting the number of implant dislocations
Implant Survival	3 years postoperatively, due to early study termination	Represents the implants that survived by counting the number of implants revised.

Secondary Outcome Measures

Name	Time	Method
Evaluation of Pain and Functional Performance Determined by the Harris Hip Score	3 years postoperatively, due to early study termination	The Harris Hip Score is a questionnaire filled by the surgeon on the patients who received a hip implant. The domains covered are pain, function, absence of deformity, and range of motion. The pain domain measures pain severity and its effect on activities and need for pain medication. The function domain consists of daily activities (stairs, public transportation, sitting, and managing shoes and socks) and gait (limp, support needed for walking, and walking distance). Deformity takes into account hip flexion, adduction, internal rotation, and extremity length discrepancy. Range of motion measures hip flexion, abduction, external and internal rotation, and adduction. There are 10 items. The score has a minimum of 0 (worst possible score) to a maximum of 100 points (best possible outcome) covering pain (1 item, 0-44 points), function (7 items, 0-47 points), absence of deformity (1 item, 4 points), and range of motion (2 items, 5 points).
Confirmation of Safety Based on Complications	3 years postoperatively, due to early study termination	Reported number of patients with adverse events related to the implant. Adverse events include: dislocations of the hip, revisions and removals of the implants